 "Lupin receives US FDA tentative approval for antibacterial drug moxifloxacin")
Lupin Limited has received tentative approval for moxifloxacin hydrochloride tablet, an antibacterial drug, from the US Food and Drug Administration (FDA).
The company’s US subsidiary, Gavis Pharmaceuticals LLC, USA has received tentative approval for its moxifloxacin hydrochloride tablet, 400 mg from the US FDA to market a generic version of Bayer Healthcare Pharmaceuticals Inc’s Avelox tablet, 400 mg (base),” said Lupin in a press release.
Lupin’s moxifloxacin hydrochloride tablet is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria in certain conditions.
Avelox had US sales of $ 30.1 million, according to IMS MAT June 2016.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%